regular dose of JiRui® Prunella oral liquid
DrugTake 10ml twice a day
NCT Number: NCT06423235
A multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of Prunella oral liquid in patients with benign thyroid nodules, which belongs to the post-marketing reevaluation clinical study.
In this study, 234 subjects will be enrolled by competitive enrollment at several research centers across China. The main inclusion criteria are:
① Thyroid ultrasound examination found thyroid nodules, can be accompanied by goiter, and the nodules meet the following conditions: 1) There were dominant nodules in single or multiple nodules (the largest diameter of the second largest nodules was not more than 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules was ≥1cm and < 3cm, 4) C-TIRADS 3~4A nodules.
② Patients who met the puncture indication were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda II).
③ Levels of TSH, FT3 and FT4 were normal, and the antibody titers of TgAb and TPOAb were normal.
Eligible subjects will be randomly assigned on a 1:1:2:2 scale to: Group A (placebo conventional dose group, 10 mL/times, 2 times/day), group B (placebo 2x dose group, 10ml/times, 2 times/day), group C (conventional dose group of Prunella oral liquid), group D (Prunella oral liquid 2x dose group). All subjects will receive the treatment for 9 months and follow up at 3rd, 6th, 9th and 12th month.
The primary efficacy endpoint of this study was the rate of change in thyroid nodule volume from baseline at 9 months of treatment. The rate of change in thyroid nodule volume from baseline at 3 and 6 months of treatment was a secondary efficacy endpoint. Other secondary efficacy endpoints included maximum thyroid nodule diameter, number of thyroid nodules, proportion of patients with reduced thyroid nodule volume or ≥50% from baseline, thyroid volume, thyroid function (serum TSH, FT3, FT4, thyroid egg levels (Tg), thyroid antibody levels (TgAb, TPOAb), quality of life evaluation (SF-36), etc. Safety endpoints included incidence of AE/ serious adverse events (SAE), causality, and outcomes. Incidence of AE/SAE leading to discontinuation. Changes in safety laboratory test values from baseline.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Phase 4
Second Hospital of Army Military Medical University, Chongqing, Chongqing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Take 10ml twice a day
Take 20ml twice a day
Take 10ml twice a day
Take 20ml twice a day
Time frame: 270 ± 14 days
Time frame: 90 ± 7 days.
Time frame: 180 ± 10 days.
Time frame: 360 ± 14 days.
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 180 ± 10 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Time frame: 90 ± 7 days
Time frame: 180 ± 10 days
Time frame: 270 ± 14 days
Time frame: 360 ± 14 days
Contact information is provided by the study sponsor or research team.
Biao Chen
CONTACT
Wenjing Ji
CONTACT
Xintian Pharmaceutical
Industry
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study
Acronym: ESPTTN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07428057
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Minya, Minya Governorate, Egypt
View Trial DetailsNCT06738888
Endocrine Gland Neoplasms, Endocrine System Diseases
Shanghai, China
View Trial DetailsNCT06730321
Adenocarcinoma, Adenocarcinoma, Papillary
Shanghai, China
View Trial DetailsNCT07287176
Ablation, Endocrine Gland Neoplasms
Sarasota, Florida, United States
View Trial Details